Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study

Rhea-AI Summary

Inspire Medical Systems (NYSE: INSP) will showcase new clinical data and technology at SLEEP 2026 in Baltimore. Highlights include Inspire V system performance, cardiovascular outcomes research, and the publication of the PREDICTOR study.

Data cover hypoxic burden, long-term registry outcomes, and comparisons between hypoglossal nerve stimulation, CPAP, and no treatment.

News Market Reaction – INSP

+0.63%

+0.63% Session close to close

In the Jun 16 session, INSP gained 0.63%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds substantial clinical and outcomes evidence around Inspire therapy, spanning r...

Analysis

This announcement adds substantial clinical and outcomes evidence around Inspire therapy, spanning randomized analyses, real‑world databases, and a 5,000-patient registry. The data highlight reductions in hypoxic burden, improved cardiovascular risk markers, and higher adherence versus CPAP, alongside workflow gains with the Inspire V system. In context of earlier guidance-related volatility, investors may track how these results translate into adoption, procedure volumes, and future updates to revenue outlook and reimbursement dynamics.

Key Figures

Matched cohort size: 3,525 patients per group Inspire V study size: 44 participants Implant time reduction: 20.4% +5 more

8 metrics

Matched cohort size 3,525 patients per group TriNetX comparison of HNS vs CPAP

Inspire V study size 44 participants Next-generation HGNS therapy final study results

Implant time reduction 20.4% Inspire V vs Inspire IV implant time

Respiratory sensing overlap 87.1% vs 79.4% Inspiratory Phase Overlap vs Inspire IV system

AHI change 25.5 events/hour decrease From median AHI 34.4 to 8.4 in Inspire V study

ADHERE registry size 5,000 participants Longitudinal hypoglossal nerve stimulation registry

Median AHI reduction 62% decrease Post-titration sleep studies in ADHERE registry

Inspire adherence vs CPAP 93% vs 56% at 30 days Real-world comparison of compliance after transition from CPAP

Historical Context

5 past events · Latest: Jun 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 12	Conference participation	Neutral	+1.3%	Announcement of participation in Wells Fargo 2026 MedTech Innovation Spotlight.
May 04	Earnings and guidance	Negative	-12.0%	Q1 2026 results with narrowed full-year revenue guidance below 2025 levels.
Apr 29	Conference presentation	Neutral	-3.1%	Planned presentation at BofA Securities 2026 Healthcare Conference.
Apr 06	Earnings date notice	Neutral	-1.6%	Scheduling of Q1 2026 earnings release and conference call details.
Mar 03	Investor forum appearance	Neutral	+1.5%	Announcement of participation in KeyBanc Capital Markets Healthcare Forum.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent company updates, especially earnings and guidance changes, have tended to see share price moves consistent with the tone of the news, while conference and presentation announcements have produced relatively modest reactions.

Recent Company History

Over the last few months, INSP has mainly issued conference participation and investor event notices alongside a key earnings update. The May 4, 2026 Q1 results and guidance revision were followed by a -12.02% move, reflecting sensitivity to financial outlook. By contrast, news of upcoming presentations at KeyBanc, BofA, and Wells Fargo conferences saw smaller moves between about -3% and +1.5%. Today’s detailed clinical and outcomes data add to that backdrop by emphasizing therapy performance rather than financial metrics.

Key Terms

hypoxic burden, apnea-hypopnea index, drug-induced sleep endoscopy, hypoglossal nerve stimulation, +4 more

8 terms

hypoxic burden medical

"Significant reductions in hypoxic burden, a key physiologic measure of oxygen desaturation"

Hypoxic burden is a measure of how much and how long a person's blood oxygen levels fall below normal, combining the depth and duration of low-oxygen events into a single score. Investors care because it is used to evaluate the severity of respiratory and sleep disorders, guide treatment decisions, and influence demand for medical devices, drugs and diagnostics — like knowing how often and how badly a car runs low on fuel, which affects maintenance and replacement needs.

apnea-hypopnea index medical

"independent of AHI or arousal index changes"

A measure of how often a person has pauses or shallow breaths during sleep, calculated as the average number of these events per hour. Investors care because this single number is used by doctors and insurers to diagnose sleep-disordered breathing and decide on treatments and device coverage, so higher or lower values can affect demand for diagnostic tools, therapies, and related healthcare spending—think of it as counting traffic jams per hour to judge road congestion.

drug-induced sleep endoscopy medical

"without requiring drug-induced sleep endoscopy (DISE)"

A drug-induced sleep endoscopy is a diagnostic procedure in which a clinician gives medications to make a patient sleep-like and then uses a small flexible camera to observe the throat and upper airway in real time to locate where breathing is blocked. It matters to investors because clearer, individualized diagnoses can change which medical devices, surgeries or therapies are used, affecting demand and outcomes—think of it as mapping a clogged pipe to choose the right repair.

hypoglossal nerve stimulation medical

"The hypoglossal nerve stimulation cohort had significantly lower odds of stroke"

Hypoglossal nerve stimulation is a medical-device therapy that uses a small implanted pulse generator to gently activate the nerve controlling the tongue, keeping the airway open during sleep to reduce obstructive sleep apnea. For investors it matters because it is a regulated implantable technology whose clinical effectiveness, safety profile, approval status and reimbursement determine patient adoption, sales growth and long-term revenue potential—similar to how a pacemaker’s performance drives demand in heart care.

continuous positive airway pressure medical

"Inspire therapy versus Continuous Positive Airway Pressure (CPAP) and untreated populations"

A medical therapy delivered by a small machine that blows a steady stream of pressurized air through a mask to keep the throat and upper airway open during sleep, preventing pauses in breathing. Investors care because demand, device sales, replacement parts and service, regulatory approvals and insurance reimbursement directly affect manufacturers’ and suppliers’ revenues—think of it like a household appliance that requires ongoing purchases and occasional upgrades.

major adverse cardiovascular events medical

"reduction of 8 of 9 MACE diagnoses while CPAP therapy was associated"

Major adverse cardiovascular events (often abbreviated MACE) are a grouped set of serious heart- and blood-vessel problems—commonly heart attack, stroke, and death from cardiovascular causes—used as a single “scorecard” in clinical studies. Investors watch MACE results because they directly affect whether a treatment or device is seen as safe and effective, which in turn shapes regulatory approval, market access, potential sales, and legal or reputational risk.

epworth sleepiness scale medical

"daytime sleepiness using the Epworth Sleepiness Scale (ESS)"

A short self-report questionnaire that asks people to rate how likely they are to doze off in common daily situations, producing a single score that reflects overall daytime sleepiness. Investors follow it because the score is often used as a clinical trial endpoint and regulatory or labeling measure for sleep disorder treatments and devices; like a thermometer for daytime sleepiness, it helps show whether a therapy meaningfully improves patients and supports market potential.

target trial emulation technical

"Target Trial Emulation of Hypoglossal Nerve Stimulation and Cardiovascular Outcomes"

Target trial emulation is a method for using existing observational data to mimic a randomized clinical trial so researchers can estimate what would have happened if people had been randomly assigned to different treatments. For investors, it matters because it provides a more reliable way to judge a drug’s or product’s real-world effectiveness and safety when randomized trials aren’t available, helping assess commercial potential and regulatory or liability risk—like reconstructing a recipe from a finished dish to understand how it was made.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Highlights New Clinical Data, Technology Advancements, and Cardiovascular Outcomes Research

MINNEAPOLIS, June 16, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced its participation in SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14–17 in Baltimore, Maryland.

SLEEP is the premier global forum for sleep medicine and research, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).

Advancing Innovation and Clinical Evidence

“We are pleased to return to SLEEP and showcase the continued evolution of the Inspire platform, including the Inspire V system, alongside compelling new clinical data demonstrating real-world effectiveness,” said Tim Herbert, Chairman and Chief Executive Officer. “Our long-standing partnership with SLEEP reflects our commitment to advancing physician education and improving outcomes for patients with OSA worldwide.”

At Booth #525, attendees can explore:

• The Inspire V system and recent technology advancements
• Clinical evidence supporting closed-loop therapy detailing respiratory sensing and inspiratory overlap
• The Inspire SleepSync™ remote patient management platform
• Resources for establishing and scaling Inspire programs
  
  

New Clinical Insights: Hypoxic Burden and Cardiovascular Outcomes

Multiple presentations at SLEEP 2026 will highlight the growing body of evidence supporting Inspire therapy, particularly in improving cardiovascular risk markers. Separately, Inspire will highlight additional research at its exhibit booth, including recent peer-reviewed articles on hypoxic burden and cardiovascular outcomes, which complement these presentations and are not being presented as part of the SLEEP 2026 program.

The first article from Dr. Xu¹ is a secondary analysis from the STAR trial that demonstrated:

• Significant reductions in hypoxic burden, a key physiologic measure of oxygen desaturation linked to OSA risk
• Improvements in daytime sleepiness that correlate with hypoxic burden reduction, independent of AHI or arousal index changes
• Meaningful hypoxic burden improvements in at least 50% of AHI non-responders, supporting its role as a complementary biomarker
• Hypoxic burden is a measure of the total impact of oxygen desaturation events during sleep, integrating the depth, duration, and frequency of these events to quantify sleep apnea severity
  
  

These findings reinforce hypoxic burden as an emerging and clinically relevant endpoint and align with a growing number of studies evaluating cardiovascular outcomes in patients treated with Inspire therapy versus Continuous Positive Airway Pressure (CPAP) and untreated populations.

1 – Xu et al, Hypoglossal Nerve Stimulation and Hypoxic Burden in Patients with Obstructive Sleep Apnea - A Secondary Analysis of the STAR Trial; JAMA Otolaryngology Head Neck Surg. doi:10.1001/jamaoto.2026.1049 Published online May 21, 2026

The second article from Dr. Nayak² compared clinical outcomes between HNS and CPAP in OSA patients using data from the TriNetX database and compared a matched group of 3,525 patients in each group (CPAP and Inspire therapy).

• OSA is linked to cardiovascular, metabolic, and neuropsychiatric morbidity
• The hypoglossal nerve stimulation cohort had significantly lower odds of stroke, myocardial infarction, atrial fibrillation/flutter, hypertensive crisis, pulmonary embolism, ventricular tachycardia, COPD exacerbation, acute kidney injury, hospitalization, acute heart failure, and others
• Hypoglossal nerve stimulation may offer systemic benefits and reduce healthcare burden compared to CPAP
  
  

2 – Nayak et al, Clinical Outcomes of Hypoglossal Nerve Stimulation Versus Continuous Positive Airway Pressure in Obstructive Sleep Apnea; OTO Open 2026, Vol. 10(2):e70240 April-June 2026

PREDICTOR Study Publication

Inspire also announced the publication of the PREDICTOR study³, which identified body mass index and neck circumference as predictors of complete concentric collapse. These findings suggest that many patients may be screened for Inspire therapy eligibility without requiring drug-induced sleep endoscopy (DISE), potentially reducing diagnostic burden, time to treatment, and healthcare costs.

3 – Weiner et al, Anthropometric Measurements Inform Complete Concentric Collapse Status in Patients with Obstructive Sleep Apnea; OTO Open 2026, Vol. 10(2):e70245 April-June 2026

Key Data Presentations

Sessions of Interest

• June 16 | 10:00 – 10:45 AM | Room 341
  Target Trial Emulation of Hypoglossal Nerve Stimulation and Cardiovascular Outcomes
• June 16 | 11:45 AM – 12:45 PM | Holiday Ballroom 4–5
  Long-Term Cardiovascular Outcomes Following HGNS Therapy
  
  

Highlighted Poster Presentations

10:00 a.m. to 11:45 a.m. Tuesday, June 16, Exhibit Hall G

• Next-Generation Hypoglossal Nerve Stimulation Therapy for the Treatment of Obstructive Sleep Apnea: Final Study Results
  • 44 participants enrolled and successfully implanted with no device revisions or explants
  • Inspire V implant times decreased by 20.4% compared to the Inspire IV system
  • Respiratory sensing as demonstrated by Inspiratory Phase Overlap demonstrated superiority to the Inspire IV system at 87.1% vs. 79.4%
  • Mean AHI decrease of 25.5 events per hour from median AHI of 34.4 at baseline to 8.4
  • Mean adherence at 5.9 hours of usage per night

• Evaluation of a Next-Generation Unilateral Hypoglossal Nerve Stimulation with Respiratory Sensing Platform: Data from the Limited Market Release
  • Retrospective review of 41 patients implanted with Inspire V during a limited market release
  • Mean nightly therapy usage of 6.21 hours per night over the 30 days following in-lab post-titration sleep study
  • 97.6% of patients self-reported experiencing benefit from Inspire therapy

• Comprehensive Assessment of a 5,000 Patient Longitudinal Hypoglossal Nerve Stimulation Registry: Final Results of the ADHERE Registry
  • The ADHERE registry was designed to enroll 5,000 participants implanted with a hypoglossal nerve stimulation device throughout the U.S. and Europe
  • Baseline information included demographics, medical history, sleep study results, and daytime sleepiness using the Epworth Sleepiness Scale (ESS)
  • Post-titration sleep studies show a 62% median decrease in AHI
  • Significant improvement in daytime sleepiness with ESS score of 6 at post-titration and final follow-up
  • 6.4 hours per night mean therapy usage at post-titration and 5.8 hours per night at final visit
  • 90% of physicians saw improvement in their patients
    
    
• A Target Trial Emulation of Hypoglossal Nerve Stimulation Therapy for OSA and Cardiovascular Outcomes – Late breaking abstract
  
  
  • Independent study using the Definitive Healthcare Atlas database in which 4,388 Inspire therapy patients were matched up with adherent CPAP patients, non-adherent CPAP patients, and those who remained untreated  
  • Compared to untreated patients, Inspire therapy was associated with the reduction of 8 of 9 MACE diagnoses while CPAP therapy was associated with the reduction of 6 of 9 MACE diagnoses
  • Inspire therapy is estimated to reduce the risk of MACE diagnoses compared to CPAP therapy and no treatment

• Real World Comparison of Patient Compliance and Efficacy Using Continuous Positive Airway Pressure versus Hypoglossal Nerve Stimulation
  • Independent retrospective study examined 45 patients from 2016 to 2024 with moderate to severe OSA initially treated with CPAP who later transitioned to Inspire therapy
  • Inspire therapy adherence was demonstrated to exceed CPAP adherence at 93% at 30 days as compared to 56% for CPAP and 91.7% at 90 days as compared to 56% for CPAP
  • Inspire therapy demonstrated approximately 65% greater median disease alleviation than CPAP, primarily through improved adherence over 90 days
  • Superior adherence may improve long-term cardiovascular and quality-of-life outcomes
    
    

About AASM
The American Academy of Sleep Medicine is the only professional society in the U.S. dedicated exclusively to the medical subspecialty of sleep medicine. The AASM improves sleep health and promotes high quality, patient-focused care through advocacy, education, evidence-based research, and practice standards.

About SRS
The Sleep Research Society is an organization for scientific investigators who educate and research sleep and circadian science. The SRS serves its members and the field of sleep research through training and education, and by providing forums for the collaboration and the exchange of ideas.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Safe Harbor for Forward-Looking Statements and Additional Disclosure Considerations
This press release contains forward-looking statements, including statements regarding potential clinical outcomes, the interpretation of clinical data and the expected adoption and use of Inspire therapy. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the factors identified in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and as such factors may be updated from time to time in our filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com.

The clinical studies and publications referenced in this press release vary in design, patient populations, endpoints, and methodologies. As a result, outcomes across studies are not directly comparable, and findings from observational or retrospective analyses may not establish causation. Certain statements also involve comparisons to alternative therapies; such comparisons are based on individual study findings and should be interpreted with caution. These data should be considered in the context of the limitations of each study and the broader body of clinical evidence.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443

FAQ

What is Inspire Medical Systems (NYSE: INSP) presenting at SLEEP 2026?

Inspire Medical Systems is presenting new clinical data, cardiovascular outcomes research, and technology updates at SLEEP 2026. According to Inspire Medical Systems, highlights include Inspire V system results, large registry findings, comparative studies versus CPAP, and publication of the PREDICTOR study on screening eligibility.

What are the key Inspire V hypoglossal nerve stimulation results shared at SLEEP 2026 for INSP?

Inspire reported next-generation Inspire V data from 44 implanted participants with no device revisions or explants. According to Inspire Medical Systems, implant times fell 20.4%, median AHI dropped from 34.4 to 8.4 events per hour, and mean nightly usage was 5.9 hours.

What did the PREDICTOR study reveal about screening patients for Inspire (INSP) therapy?

The PREDICTOR study identified body mass index and neck circumference as predictors of complete concentric collapse. According to Inspire Medical Systems, these findings suggest many obstructive sleep apnea patients may be screened for Inspire therapy eligibility without drug-induced sleep endoscopy, potentially reducing diagnostic burden, time to treatment, and healthcare costs.

How do hypoglossal nerve stimulation outcomes compare with CPAP in recent INSP-related research?

A study by Dr. Nayak compared hypoglossal nerve stimulation and CPAP in matched obstructive sleep apnea cohorts of 3,525 patients each. According to Inspire Medical Systems, the stimulation group showed significantly lower odds of multiple cardiovascular and systemic events, suggesting potential systemic and healthcare utilization benefits versus CPAP.

What long-term ADHERE registry results did Inspire Medical Systems (INSP) highlight at SLEEP 2026?

Inspire highlighted final ADHERE registry results from 5,000 hypoglossal nerve stimulation patients in the U.S. and Europe. According to Inspire Medical Systems, median AHI decreased 62%, Epworth Sleepiness Scale scores reached 6 at follow-up, nightly usage remained about 5.8–6.4 hours, and 90% of physicians reported patient improvement.

What did the target trial emulation show about Inspire therapy and major adverse cardiovascular events (MACE)?

A target trial emulation matched 4,388 Inspire therapy patients with adherent CPAP, non-adherent CPAP, and untreated groups. According to Inspire Medical Systems, Inspire therapy was associated with reduction in 8 of 9 MACE diagnoses versus untreated patients and was estimated to reduce MACE risk versus CPAP and no treatment.

How did real-world adherence to Inspire therapy compare with CPAP in the INSP-related retrospective study?

A retrospective study of 45 moderate to severe obstructive sleep apnea patients transitioning from CPAP to Inspire therapy found higher Inspire adherence. According to Inspire Medical Systems, adherence was 93% vs. 56% at 30 days and 91.7% vs. 56% at 90 days, with about 65% greater median disease alleviation.